

BelHealth Investment Partners Acquires Precision Toxicology

** Leading West Coast-based provider of clinical toxicology services*

** BelHealth will accelerate growth from regional company to national platform*

New York, NY – May 1, 2014 – BelHealth Investment Partners (“BelHealth”), a healthcare-focused private equity firm, announced today the acquisition of Precision Toxicology (“Precision” or the “Company”).

Precision, headquartered in San Diego, California, is a clinical laboratory that specializes in providing quantitative drug testing, primarily for the purpose of helping physicians monitor their patients undergoing treatment for pain or substance abuse. Precision’s objective is to improve patient adherence/compliance with their prescription regimen and protect medical practices from liability. The Company has experienced rapid growth since inception and will continue to expand its successful strategy throughout the rest of the country, becoming a leading, national clinical toxicology lab.

Dennis Drislane, BelHealth Managing Partner, stated, “Toxicology is one of the fastest growing segments of the laboratory industry. We have evaluated several companies in the segment and determined that Precision offers the best opportunity to take advantage of the market tailwinds and build a leading, national toxicology lab. Precision is managed by two young entrepreneurs, Jason Hansen and Miguel Gallego, who understand the importance of strong compliance and operating a business the right way in a highly scrutinized industry. Jason and his team are incredibly talented and with the right infrastructure to support them, have the potential for exponential growth. We are thrilled about the potential of this investment partnership.”

Precision is BelHealth’s fifth platform company, and is a great fit because of the enormous synergy opportunities between Precision and some of the other BelHealth portfolio companies. For example, Linden Care, the leading specialty pharmacy in the U.S. with a focus on pain pharmaceuticals, has nearly 5,000 relationships with physicians that routinely prescribe pain medications. Precision will leverage Linden Care’s physician relationships to cross sell its drug testing services. As another example, General Genetics Corporation (GGC), a clinical genetic testing laboratory, provides pharmacogenetic testing that helps physicians understand how rapidly a patient metabolizes pain medications. There is an opportunity for Precision, Linden Care and GGC to not only benefit from cross selling, but to create a comprehensive pain management solution. This solution would be unique in the market and appeal to physicians, to help guide better treatment decisions, and payors, which are seeking to control the rapid rise in cost of pain management.

Jason Hansen, founder and Chief Executive Officer of Precision will retain a significant investment in the business and join the board of directors. Mr. Hansen commented, “I am excited to have the resources and experience of BelHealth to help us accelerate our growth. We are proud of the success that we have achieved to date and look forward to leveraging the vast resources and experience of BelHealth to build Precision into a leading national toxicology lab. BelHealth’s healthcare industry expertise and the tremendous opportunity to leverage Linden Care’s thousands of physician relationships made BelHealth our ideal partner. We look forward to a successful partnership.”

About BelHealth Investment Partners

BelHealth Investment Partners, based in New York, is a healthcare private equity firm focused on lower middle market companies. BelHealth acquires majority positions in entrepreneur-owned companies we believe would benefit from our vast operating and private equity experience. The firm typically invests \$10-25 million per platform company across four healthcare segments: Services, Products, Distribution and Information Technology. Applying an active, hands-on approach, BelHealth utilizes its experience to support management to drive revenue, profit growth and achieve superior returns for our investors and partners.

For further information, please visit:

Precision Toxicology: www.precisiontoxicology.com

BelHealth Investment Partners: www.belhealth.com

Contact:

Precision Toxicology: Jason Hansen (800) 635-6901

BelHealth Investment Partners: David Sturek (347) 308-7019